Lunai Bioworks Inc./$LNAI
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Lunai Bioworks Inc.
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.
Ticker
$LNAI
Sector
Primary listing
Employees
29
Headquarters
Website
LNAI Metrics
BasicAdvanced
$24M
-
-$7.22
0.36
-
Price and volume
Market cap
$24M
Beta
0.36
52-week high
$1.66
52-week low
$0.81
Average daily volume
2.3M
Financial strength
Current ratio
0.041
Quick ratio
0.032
Long term debt to equity
-2.139
Total debt to equity
-20.757
Interest coverage (TTM)
-25.58%
Profitability
EBITDA (TTM)
-15.161
Management effectiveness
Return on assets (TTM)
-14.85%
Return on equity (TTM)
-308.01%
Valuation
Price to book
-1.83
Price to tangible book (TTM)
-1.25
Price to free cash flow (TTM)
-2.592
Free cash flow yield (TTM)
-38.58%
Free cash flow per share (TTM)
-0.397
Growth
Earnings per share change (TTM)
-29.00%
3-year earnings per share growth (CAGR)
-29.71%
LNAI News
AllArticlesVideos
Lunai Bioworks Harnesses AI and Zebrafish Data to Advance Early Detection of Neurotoxic Compounds
Accesswire·2 months ago
Landmark Study Identifies Prognostic Biomarkers in Duchenne Muscular Dystrophy Using Large-Scale Serum Proteomics
Accesswire·2 months ago
Lunai Bioworks Regains Compliance with Nasdaq Minimum Bid Price Requirement
Accesswire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Lunai Bioworks Inc. stock?
Lunai Bioworks Inc. (LNAI) has a market cap of $24M as of December 19, 2025.
What is the P/E ratio for Lunai Bioworks Inc. stock?
The price to earnings (P/E) ratio for Lunai Bioworks Inc. (LNAI) stock is 0 as of December 19, 2025.
Does Lunai Bioworks Inc. stock pay dividends?
No, Lunai Bioworks Inc. (LNAI) stock does not pay dividends to its shareholders as of December 19, 2025.
When is the next Lunai Bioworks Inc. dividend payment date?
Lunai Bioworks Inc. (LNAI) stock does not pay dividends to its shareholders.
What is the beta indicator for Lunai Bioworks Inc.?
Lunai Bioworks Inc. (LNAI) has a beta rating of 0.36. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.